Salarius Pharmaceuticals Inc. (SLRX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
SLRX Chart
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT04734990.
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRX
NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Salarius Pharmaceuticals, Inc. ( Nasdaq : SLRX ), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.
Salarius Pharmaceuticals Inc. Dividends
Salarius Pharmaceuticals Inc. Earnings
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 20 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 20 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Salarius Pharmaceuticals Inc. (SLRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Salarius Pharmaceuticals Inc. ever had a stock split?
Salarius Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. David J. Arthur M.B.A. CEO | NASDAQ (CM) Exchange | 79400X404 Cusip |
| US Country | 2 Employees | - Last Dividend | 17 Jun 2024 Last Split | 29 Jan 2015 IPO Date |
Overview
Salarius Pharmaceuticals, Inc. is a trailblazing clinical-stage biotechnology firm devoted to the innovation of treatments for cancers that lack sufficient medical solutions. Positioned at the forefront of cancer research, the company's dynamism is rooted in its relentless pursuit to address and fulfill unmet medical needs through groundbreaking research and development. Salarius is distinguished by its strategic partnerships, one with The University of Utah Research Foundation, granting it exclusive rights to crucial patent protections for its leading compound and related chemicals, and another significant collaboration with the Cancer Prevention and Research Institute of Texas, which supports its product development initiatives. Operating from its headquarters in Houston, Texas, Salarius Pharmaceuticals, Inc. embodies a beacon of hope in the ongoing battle against cancer, demonstrating a steadfast commitment to advancing oncological care through scientific innovation and strategic alliances.
Products and Services
- Seclidemstat (SP-2577)
This pioneering compound serves as Salarius Pharmaceuticals' flagship candidate, exemplifying the company's dedication to cancer research. Positioned in the critical Phase I/II clinical trial stage, Seclidemstat targets advanced solid tumors and Ewing sarcoma. Its mechanism as a small molecular inhibitor sets a precedent in the therapeutic landscape, offering a novel approach to combat these formidable cancers. The promise of Seclidemstat extends beyond its current trial phase, highlighting Salarius's commitment to addressing and overcoming challenges in oncology.
- SP-3164
Expanding its arsenal in the fight against cancer, Salarius introduces SP-3164, a sophisticated small molecular protein degrader. This formidable agent is designated for the treatment of both hematological malignancies and solid tumors, showcasing the company's versatile approach to cancer therapy. SP-3164 represents Salarius’s endeavor to diversify its therapeutic portfolio, aiming at broader targets in the oncology spectrum and underscoring its innovative spirit and relentless pursuit of cancer eradication.
Contact Information
